Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCA101 in advanced solid tumors
NCT05547906Phase 1Completed
- Sponsor
- MetaFines
- Start
- Nov 2021
- Primary completion
- Feb 2024
- Modality
- Large molecule
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ASCA101 in solid tumor (advanced stage), sponsored by MetaFines. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Nov 2021; status: completed.
02
Drugs
ASCA101
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05547906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547906.